Hydrazine sulfate (Sehydrin) 60 mg – [50 tablets]

The drug inhibits tumor growth, affects a number of biochemical parameters: inhibits monoamine oxidase activity, reduces the permeability of cell membranes and biomembranes of subcellular structures, is an inhibitor of xenobiotics metabolism. It has symptomatic therapeutic effect in malignant neoplasms in advanced stages. It does not have myelodepressive and other side effects typical for many other anticancer drugs. Antitumor agent, inhibits the growth of tumor cells, inhibits MAO, inhibits gluconeogenesis, reduces the permeability of biomembranes of subcellular structures. It has symptomatic therapeutic effect in malignant neoplasms in advanced stages. It does not have myelodepressive and other side effects characteristic for many other antitumor drugs. It reduces pain syndrome, weakness, respiratory failure phenomena (dyspnea, cough), hyperthermia, improves appetite, motor activity, mood and well-being.

Symptomatic treatment of locally advanced and disseminated forms of malignancy. Sehydrin® has marked symptomatic action: reduction or elimination of pain syndrome (up to withdrawal), weakness, respiratory failure phenomena (dyspnea), cough, fever, improved appetite, increased motor activity. The drug is prescribed to patients with malignant tumors in advanced stages (including in the preterminal phase of the process).

– Hypersensitivity to hydrazine sulfate and other components of the drug;

– concomitant use with all kinds of alcohol and barbiturates;

– Pregnancy and lactation;

– Childhood (in connection with the lack of experience of application).

With caution:

In marked hepatic and renal dysfunction.